Aevi Genomic Medicine, LLC, a Cerecor company

Quick facts

Phase 2 pipeline

• AEVI-001 · Oncology
  AEVI-001 is a small molecule drug that targets the PI3K/AKT pathway.
• CERC-002
• NFC-1

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aevi Genomic Medicine, LLC, a Cerecor company portfolio CI brief
• Aevi Genomic Medicine, LLC, a Cerecor company pipeline updates RSS

Related

• Sector hub: All tracked pharma companies